Deadline to Complete OAT-CAMPP Training in Community Pharmacy: September 30, 2021
[Last Updated on October 01, 2021]
The deadline to complete the Opioid Agonist Treatment Compliance and Management Program (OAT-CAMPP) is September 30, 2021.
As of October 1, 2021, all pharmacy managers, staff pharmacists, relief pharmacists and pharmacy technicians employed in a community pharmacy that provides pharmacy services related to opioid agonist treatment must complete any applicable component(s) of OAT-CAMPP in order to fulfill the College’s Opioid Agonist Treatment training requirements as outlined in Professional Practice Policy-66: Opioid Agonist Treatment (PPP-66).
Registrants who have not completed the required training should do so as soon as possible. During the ongoing opioid overdose crisis, it is in the public interest to maintain patient OAT treatment wherever possible.
In addition, PharmaCare will require every pharmacist at a pharmacy that provides opioid agonist treatment to have completed the OAT-CAMPP training by October 1, 2021. OAT-CAMPP training will also be required for pharmacies to enrol in the OAT provider sub-class and to maintain enrolment. (See PharmaCare Newsletter Edition 21-008: August 4, 2021 OAT training: deadline reminder)
With British Columbia’s opioid overdose crisis continuing to escalate, it is essential for all professionals involved in providing OAT services to have completed the OAT-CAMPP training. This is required to provide OAT services as part of the College’s Professional Practice Policy-66: Opioid Agonist Treatment and is an important step to ensure all pharmacy professionals who are involved in caring for those affected by this public health emergency have been trained with the most up-to-date research, pharmacological treatments, and patient-centred approach.
As of October 1, 2021 pharmacy professionals are reminded that the OAT-CAMPP training will be required in pharmacies that provide OAT services.
The College’s Methadone Maintenance Treatment (MMT) training program will no longer be available as of October 1, 2021.
About the Opioid Agonist Treatment Compliance and Management Program (OAT-CAMPP)
OAT-CAMPP was introduced on January 1, 2019 and is administered by the BC Pharmacy Association. The program was developed to address gaps in the College’s MMT training program by providing additional education for pharmacists and pharmacy technicians involved in delivering care to patients with opioid use disorder. OAT-CAMPP is aimed at reducing stigma and expanding pharmacists’ knowledge of methadone, buprenorphine/naloxone, and slow-release oral morphine.
The program, comprised of both self-study and live sessions, includes training on buprenorphine/naloxone, methadone, and slow-release oral morphine maintenance treatments, as well as on opioid use disorder itself. Additionally, with pharmacists often on the front lines of the opioid crisis, this training program also aims to improve the experience of people receiving treatment. It includes a patient-centred approach, discussing lived experiences of patients and communication strategies to reduce stigma and increase patient engagement.
Declaration of Completion
Once a pharmacist or pharmacy technician has successfully completed the College’s Opioid Agonist Treatment training requirements, they must submit a declaration of completion through the College’s eServices website.
This declaration is for pharmacy professionals who have 1) successfully completed the Opioid Agonist Treatment training program, and 2) read and understood the content of Professional Practice Policy-66: Opioid Agonist Treatment and the accompanying Policy Guides.
Note: Declarations for Injectable Opioid Agonist Treatment (iOAT), if applicable, must be submitted separately.
Learn more about submitting a declaration of successful completion of these requirements through eServices at:
For questions about the College’s Opioid Agonist Treatment requirements, including the required OAT-CAMPP Training, please contact firstname.lastname@example.org.
For questions related to submitting the Declarations through eServices, please contact email@example.com.
- Reducing stigma, improving patient treatment focus of new pharmacists’ training (BC Government)
- PharmaCare Newsletter Edition 21-008: August 4, 2021
- ReadLinks: New Opioid Agonist Treatment Training Requirements Now in Effect
- ReadLinks: New Opioid Agonist Treatment Training Requirements Coming Soon
- Opioid Agonist Treatment (CPBC)
- PPP-66 Opioid Agonist Treatment
- PPP-66 Policy Guide: Buprenorphine/Naloxone Maintenance Treatment (2018)
- PPP-66 Policy Guide: Methadone Maintenance Treatment (2013)
- PPP-66 Policy Guide: Slow Release Oral Morphine Maintenance (SROM) Treatment (2018)
- BCPhA’s Opioid Agonist Treatment (OAT) Training Program For B.C.'S Community Pharmacists